Ask AI
ProCE Banner Series

Oncology Pharmacy Think Tank: Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Enhance your understanding of patient-centered management of CDK4/6 inhibitor therapy for HR+/HER2- breast cancer based on the latest evidence and expert recommendations to support adherence and mitigate adverse events.

  ACPE-P
Who Should Attend

This activity is intended for oncology pharmacists and other healthcare professionals who care for patients with breast cancer.

All Events

Oncology Pharmacy Think Tank: Patient-Centered Management of CDK4/6 Inhibitor Therapy for HR+/HER2- Breast Cancer

Upcoming Events

February

10

2026

2:30 PM - 3:30 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to equip oncology pharmacists with the education, skills, and resources needed to provide optimal care to patients with breast cancer who are receiving or are eligible for CDK4/6 inhibitor therapy.

Target Audience
This activity is intended for oncology pharmacists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Effectively mitigate and manage toxicities associated with CDK4/6 inhibitor therapy for patients with HR+/HER2- breast cancer, including recommended dose modification strategies

  • Implement recommended strategies to improve adherence to oral CDK4/6 inhibitor therapy in patients with HR+/HER2- breast cancer

  • Employ effective techniques to address factors leading to early discontinuation of oral anticancer therapy in patients with HR+/HER2- breast cancer

Accreditation

CE Accreditation 

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC dba Decera Clinical Education. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-25-019-L01-P has been assigned to this live application-based activity (initial release date 2/10/2026). This activity is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the  activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles. 

Acknowledgement

Provided by

Provided by ProCE, LLC in collaboration with Clinical Care Options, LLC dba Decera Clinical Education.

ProCE, LLC

Supporters

Supported by educational grants from Lilly.

Lilly

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191